- PharmAust (PAA) claims its business progressed "very successfully" in the 2019 December quarter
- Its phase 2 trials using monepantel to treat dogs with cancer saw positive progress
- The company is extending the study with a new dosage and hopes to uncover a successful drug for canine treatment
- In relation to human trials, the company has submitted and MPL human trial paper for publication in a peer review journal
- In addition, its wholly-owned subsidiary, Epichem, had a positive quarter and achieved revenue of almost $970,000
- Shares in PharmAust remain flat and are trading for 9.6 cents each
PharmAust (PAA) has reported its business progressed "very successfully" in the December 2019 quarter.
Phase II Canine Trials
The clinical stage oncology company made important progress in its Monepantel (MPL) trials.
Through these trials, PharmAust showed that six of seven dogs with treatment-naive B cell lymphoma achieved progression free survival (PFS), with reductions in tumour size after 14 days of gelatin encapsulated monepantel treatment.
The company is now repeating and extending the study with a new dosage and "highly palatable" GMP formulation.
Canine patients will be given their first assessment after 14 days of treatment to determine the tablet performance. Administration will then continue for another two weeks for a total 28 day trial period.
If pet owners and the veterinarian mutually agrees, the company would like to continue long-term treatment at a reduced dose.
Ultimately, a three to six month progression-free trial will provide PharmAust with a successfully drug for treating dogs with cancer.
OnDecember 12, the company contracted four organisations from Melbourne, Sydney, Greater Western Sydney and Perth to recruit eligible dogs for referral, recruitment and treatment.
For marketing awareness, the company has even engaged a pet journalist who has started a campaign for vets and pet owners.
To further progress this trial, PharmAust manufactured an extra 8000 GMP grade tablets that are due to arrive in this current week.
Phase II Human Trial
PharmAust has now submitted the MPL human trial paper to be published in a peer review journal. It describes the historic trial conducted in Adelaide and the performance of MPL.
Additionally, the company is conducting a comicronised table pharmacokinetic study to find a tablet formula that reduces the tablet number for human trials.
In quarter two of this year, the company will undertake a third GMP monepantel tablet program to support future trials
